Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. (REAL 1)

A Multicentre, Multinational, Randomised, Parallel-group, Placebo-controlled (Double Blind) and Active-controlled (Open) Trial to Compare the Efficacy and Safety of Once Weekly Dosing of NNC0195-0092 (Somapacitan) With Once Weekly Dosing of Placebo and Daily Norditropin® FlexPro® in Adults With Growth Hormone Deficiency for 35 Weeks, Followed by a 53-week Open-label Extension Period

This study is conducted globally. The purpose is to demonstrate the efficacy of once weekly dosing of NNC0195-0092 (somapacitan) compared to placebo and once-daily dosing of somatropin (human growth hormone, hGH) after 35 weeks of treatment in adults with growth hormone deficiency.

Study Overview

• Status: Completed
• Conditions: Growth Hormone Disorder; Adult Growth Hormone Deficiency
• Intervention / Treatment: Drug: somapacitan; Drug: somatropin; Drug: placebo

• Study Type: Interventional
• Enrollment (Actual): 301
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Blacktown, New South Wales, Australia, 2148
      • Novo Nordisk Investigational Site
    • Coffs Harbour, New South Wales, Australia, 2450
      • Novo Nordisk Investigational Site
    • Darlinghurst, New South Wales, Australia, 2010
      • Novo Nordisk Investigational Site
    • St Leonards, New South Wales, Australia, 2065
      • Novo Nordisk Investigational Site
  • Queensland
    • Woolloongabba, Queensland, Australia, 4102
      • Novo Nordisk Investigational Site
  • Victoria
    • Box Hill, Victoria, Australia, 3128
      • Novo Nordisk Investigational Site
    • Parkville, Victoria, Australia, 3052
      • Novo Nordisk Investigational Site
  • Western Australia
    • Nedlands, Western Australia, Australia, 6009
      • Novo Nordisk Investigational Site
• Brazil
  • Sao Paulo
    • São Paulo, Sao Paulo, Brazil, 01228-000
      • Novo Nordisk Investigational Site
• Germany
  • Aachen, Germany, 52074
    • Novo Nordisk Investigational Site
  • Berlin, Germany, 10117
    • Novo Nordisk Investigational Site
  • Berlin, Germany, 13352
    • Novo Nordisk Investigational Site
  • Frankfurt, Germany, 60596
    • Novo Nordisk Investigational Site
  • Oldenburg, Germany, 26122
    • Novo Nordisk Investigational Site
• India
  • Andhra Pradesh
    • Hyderabad, Andhra Pradesh, India, 500034
      • Novo Nordisk Investigational Site
  • Karnataka
    • Bangalore, Karnataka, India, 560034
      • Novo Nordisk Investigational Site
  • Kerala
    • Kochi, Kerala, India, 682041
      • Novo Nordisk Investigational Site
  • Maharashtra
    • Mumbai, Maharashtra, India, 400008
      • Novo Nordisk Investigational Site
  • New Delhi
    • New Dehli, New Delhi, India, 110029
      • Novo Nordisk Investigational Site
  • Punjab
    • Chandigarh, Punjab, India, 160012
      • Novo Nordisk Investigational Site
  • Telengana
    • Hyderabad, Telengana, India, 500033
      • Novo Nordisk Investigational Site
  • West Bengal
    • Kolkata, West Bengal, India, 700032
      • Novo Nordisk Investigational Site
• Israel
  • Petah-Tikva, Israel, 49100
    • Novo Nordisk Investigational Site
  • Tel Hashomer, Israel, 52621
    • Novo Nordisk Investigational Site
  • Tel-Aviv, Israel, 64239
    • Novo Nordisk Investigational Site
• Japan
  • Bunkyo-ku, Tokyo, Japan, 113-8603
    • Novo Nordisk Investigational Site
  • Chiba-shi, Chiba, Japan, 260-8677
    • Novo Nordisk Investigational Site
  • Fukuoka-shi, Fukuoka, Japan, 812-8582
    • Novo Nordisk Investigational Site
  • Hamamatsu-shi, Shizuoka, Japan, 431-3192
    • Novo Nordisk Investigational Site
  • Itabashi-ku, Tokyo, Japan, 173-8606
    • Novo Nordisk Investigational Site
  • Kagoshima, Japan, 890-8520
    • Novo Nordisk Investigational Site
  • Kyoto-shi Kyoto, Japan, 612-8555
    • Novo Nordisk Investigational Site
  • Minato-ku, Tokyo, Japan, 105-8470
    • Novo Nordisk Investigational Site
  • Okayama, Okayama, Japan, 700-8558
    • Novo Nordisk Investigational Site
  • Sagamihara-shi, Kanagawa, Japan, 252-0375
    • Novo Nordisk Investigational Site
  • Sapporo, Hokkaido, Japan, 060-8648
    • Novo Nordisk Investigational Site
  • Sappro-shi, Hokkaido, Japan, 060 8648
    • Novo Nordisk Investigational Site
  • Tokyo, Japan, 134-0088
    • Novo Nordisk Investigational Site
  • Yamagata-shi, Yamagata, Japan, 990-9585
    • Novo Nordisk Investigational Site
  • Yokohama, Kanagawa, Japan, 222-0036
    • Novo Nordisk Investigational Site
• Latvia
  • Riga, Latvia, LV-1002
    • Novo Nordisk Investigational Site
• Lithuania
  • Kaunas, Lithuania, 50009
    • Novo Nordisk Investigational Site
  • Vilnius, Lithuania, 08661
    • Novo Nordisk Investigational Site
• Malaysia
  • Kuching, Malaysia, 93586
    • Novo Nordisk Investigational Site
  • Pulau Pinang, Malaysia, 10990
    • Novo Nordisk Investigational Site
  • Putrajaya, Malaysia, 62250
    • Novo Nordisk Investigational Site
• Norway
  • Oslo, Norway, 0027
    • Novo Nordisk Investigational Site
• Poland
  • Bialystok, Poland, 15-879
    • Novo Nordisk Investigational Site
  • Gdansk, Poland, 80-952
    • Novo Nordisk Investigational Site
  • Krakow, Poland, 31-455
    • Novo Nordisk Investigational Site
  • Warszawa, Poland, 02-507
    • Novo Nordisk Investigational Site
  • Warszawa, Poland, 04-141
    • Novo Nordisk Investigational Site
  • Wroclaw, Poland, 50-367
    • Novo Nordisk Investigational Site
  • Wroclaw, Poland, 50-311
    • Novo Nordisk Investigational Site
• Romania
  • Bucuresti, Romania, 011863
    • Novo Nordisk Investigational Site
  • Iasi, Romania, 700111
    • Novo Nordisk Investigational Site
  • Sibiu, Romania, 550166
    • Novo Nordisk Investigational Site
  • Timisoara, Romania, 300736
    • Novo Nordisk Investigational Site
  • Cluj
    • Cluj Napoca, Cluj, Romania, 400349
      • Novo Nordisk Investigational Site
  • Mures
    • Targu Mures, Mures, Romania, 540142
      • Novo Nordisk Investigational Site
• Russian Federation
  • Kazan, Russian Federation, 420061
    • Novo Nordisk Investigational Site
  • Krasnoyarsk, Russian Federation, 660022
    • Novo Nordisk Investigational Site
  • Moscow, Russian Federation, 119435
    • Novo Nordisk Investigational Site
  • Moscow, Russian Federation, 117036
    • Novo Nordisk Investigational Site
  • Novosibirsk, Russian Federation, 630099
    • Novo Nordisk Investigational Site
  • Tomsk, Russian Federation, 634050
    • Novo Nordisk Investigational Site
• South Africa
  • Gauteng
    • Johannesburg, Gauteng, South Africa, 2193
      • Novo Nordisk Investigational Site
    • Johannesburg, Gauteng, South Africa, 2013
      • Novo Nordisk Investigational Site
    • Pretoria, Gauteng, South Africa, 0044
      • Novo Nordisk Investigational Site
  • Western Cape
    • Tygerberg, Western Cape, South Africa, 7505
      • Novo Nordisk Investigational Site
• Sweden
  • Göteborg, Sweden, 413 45
    • Novo Nordisk Investigational Site
  • Stockholm, Sweden, 171 76
    • Novo Nordisk Investigational Site
  • Uppsala, Sweden, 751 85
    • Novo Nordisk Investigational Site
• Turkey
  • Adana, Turkey, 01130
    • Novo Nordisk Investigational Site
  • Istanbul, Turkey, 34098
    • Novo Nordisk Investigational Site
  • Istanbul, Turkey, 34390
    • Novo Nordisk Investigational Site
  • Izmir, Turkey, 35100
    • Novo Nordisk Investigational Site
  • Kocaeli, Turkey, 41380
    • Novo Nordisk Investigational Site
• Ukraine
  • Kiev, Ukraine, 01021
    • Novo Nordisk Investigational Site
  • Kyiv, Ukraine, 04114
    • Novo Nordisk Investigational Site
• United Kingdom
  • Birmingham, United Kingdom, B15 2TH
    • Novo Nordisk Investigational Site
  • Coventry, United Kingdom, CV2 2DX
    • Novo Nordisk Investigational Site
  • Exeter, United Kingdom, EX2 5DW
    • Novo Nordisk Investigational Site
  • Hull, United Kingdom, HU3 2RW
    • Novo Nordisk Investigational Site
  • Leeds, United Kingdom, LS9 7TF
    • Novo Nordisk Investigational Site
  • London, United Kingdom, EC1A 7BE
    • Novo Nordisk Investigational Site
  • London, United Kingdom, SE5 9RS
    • Novo Nordisk Investigational Site
  • Manchester, United Kingdom, M20 4BX
    • Novo Nordisk Investigational Site
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35233
      • Novo Nordisk Investigational Site
  • California
    • Los Angeles, California, United States, 90095
      • Novo Nordisk Investigational Site
    • Los Angeles, California, United States, 90033
      • Novo Nordisk Investigational Site
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Novo Nordisk Investigational Site
  • Georgia
    • Atlanta, Georgia, United States, 30318
      • Novo Nordisk Investigational Site
    • Roswell, Georgia, United States, 30076
      • Novo Nordisk Investigational Site
  • Kansas
    • Topeka, Kansas, United States, 66606
      • Novo Nordisk Investigational Site
  • Maryland
    • Baltimore, Maryland, United States, 21205
      • Novo Nordisk Investigational Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Novo Nordisk Investigational Site
  • Michigan
    • East Lansing, Michigan, United States, 48824
      • Novo Nordisk Investigational Site
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Novo Nordisk Investigational Site
  • Nebraska
    • Omaha, Nebraska, United States, 68105
      • Novo Nordisk Investigational Site
    • Omaha, Nebraska, United States, 68198-4120
      • Novo Nordisk Investigational Site
  • Nevada
    • Las Vegas, Nevada, United States, 89128
      • Novo Nordisk Investigational Site
    • Reno, Nevada, United States, 89511
      • Novo Nordisk Investigational Site
  • New York
    • New York, New York, United States, 10032
      • Novo Nordisk Investigational Site
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Novo Nordisk Investigational Site
  • Oregon
    • Portland, Oregon, United States, 97239
      • Novo Nordisk Investigational Site
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19107
      • Novo Nordisk Investigational Site
    • Philadelphia, Pennsylvania, United States, 19104
      • Novo Nordisk Investigational Site
    • Pittsburgh, Pennsylvania, United States, 15212
      • Novo Nordisk Investigational Site
  • Texas
    • El Paso, Texas, United States, 79935
      • Novo Nordisk Investigational Site
    • Houston, Texas, United States, 77030
      • Novo Nordisk Investigational Site
    • Plano, Texas, United States, 75093
      • Novo Nordisk Investigational Site
    • San Antonio, Texas, United States, 78229
      • Novo Nordisk Investigational Site
    • Shavano Park, Texas, United States, 78231
      • Novo Nordisk Investigational Site
  • Utah
    • Salt Lake City, Utah, United States, 84103
      • Novo Nordisk Investigational Site
  • Washington
    • Federal Way, Washington, United States, 98003
      • Novo Nordisk Investigational Site
    • Seattle, Washington, United States, 98122-5789
      • Novo Nordisk Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 23 years to 79 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female of at least 23 years of age and not more than 79 years of age at the time of signing informed consent
• Human growth hormone (hGH) treatment naïve or no exposure to hGH or growth hormone (GH) secretagogues for at least 180 days prior to randomisation with any registered or investigational hGH or GH secretagogue product (if only used in connection with stimulation tests for diagnosis of growth hormone deficiency (GHD), subjects can be included)
• If applicable, hormone replacement therapies for any other hormone deficiencies, adequate and stable for at least 90 days prior to randomisation as judged by the investigator
• FOR ALL COUNTRIES EXCEPT JAPAN:

Confirmed diagnosis of adult growth hormone deficiency (Subjects must satisfy one of the following criterion and documentation of test results must be available before randomisation (either from subjects' file or new test):

1. Insulin tolerance test (ITT) or glucagon test: a peak GH response of less than 3 ng/mL (3 mcg/L)
2. Growth hormone releasing hormone (GHRH) + arginine test according to body mass index (BMI): i) BMI less than 25 kg/m^2, a peak GH less than 11 ng/mL (11 mcg/L), ii) BMI 25-30 kg/m^2, a peak GH less than 8 ng/mL (8 mcg/L), iii) BMI greater than 30 kg/m^2, a peak GH less than 4 ng/mL (4 mcg/L)
3. Three or more pituitary hormone deficiencies and insulin like growth factor - I standard deviation score (IGF-I SDS) less than -2.0 - FOR JAPAN ONLY: Confirmed diagnosis of adult growth hormone deficiency (subjects with adult onset adult growth hormone deficiency (AGHD) need to satisfy at least one of the following criteria, subjects with a history of childhood GHD need to satisfy at least 2 of the following criteria):

a. ITT test: a peak GH of less than or equal to 1.8 ng/mL (assay using recombinant GH standard) b. glucagon test: a peak GH of less than or equal to 1.8 ng/mL (assay using recombinant GH standard) c. growth hormone releasing peptide 2 (GHRP-2) tolerance test: a peak GH of less than or equal to 9 ng/mL (assay using recombinant GH standard)

Exclusion Criteria:

• Active malignant disease or history of malignancy. Exceptions to this exclusion criterion: - Resection in situ carcinoma of the cervix uteri. Complete eradication of squamous cell or basal cell carcinoma of the skin
• Subjects with GHD attributed to treatment of intracranial malignant tumours or leukaemia, provided that a recurrence-free survival period of at least 5 years is documented in the subject's file

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NNC0195-0092 (somapacitan)	Drug: somapacitan; Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.; Other Names: NNC0195-0092
Active Comparator: Daily hGH	Drug: somatropin; Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
Placebo Comparator: Placebo; Switch to NNC0195-0092 (somapacitan) treatment in the extension period.	Drug: somapacitan; Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.; Other Names: NNC0195-0092; Drug: placebo; Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Truncal Fat Percentage (Week 34)	Change in Truncal fat percentage was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Truncal Fat Percentage (Week 87)	Change in Truncal fat percentage was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Truncal Fat Mass (Week 34)	Change in Truncal fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Truncal Fat Mass (Week 87)	Change in Truncal fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Truncal Lean Body Mass (Week 34)	Change in Truncal lean body mass was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Truncal Lean Body Mass (Week 87)	Change in Truncal lean body mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Total Fat Mass (Week 34)	Change in Total fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Total Fat Mass (Week 87)	Change in total fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).	Week -3, week 87
Change in Visceral Adipose Tissue (Week 34)	Change in Visceral adipose tissue was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Visceral Adipose Tissue (Week 87)	Change in Visceral adipose tissue was measured from baseline (week -3) until the end of the extension treatment period (week 87).	Week -3, week 87
Change in Android Fat Mass (Week 34)	Change in Android fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Android Fat Mass (Week 87)	Change in Android fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Gynoid Fat Mass (Week 34)	Change in Gynoid fat mass was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Gynoid Fat Mass (Week 87)	Change in Gynoid fat mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Appendicular Skeletal Muscle Mass (Week 34)	Change in Appendicular skeletal muscle mass was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Appendicular Skeletal Muscle Mass (Week 87)	Change in Appendicular skeletal muscle mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Lean Body Mass (Week 34)	Change in Lean body mass was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Lean Body Mass (Week 87)	Change in Lean body mass was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Bone Mineral Content (Week 87)	Change in Bone mineral content was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Bone Mineral Density (Week 87)	Change in Bone mineral density was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in IGF-I SDS (Week 34)	Change in insulin-like growth factor (IGF-I) standard deviation scores (SDS) was measured from baseline (week -3) until the end of the main treatment period (week 34). A higher score reflects a better outcome.	Week -3, week 34
Change in IGF-I SDS (Week 87)	Change in IGF-I SDS was measured from baseline (week -3) until the end of the extension treatment period (week 87). A higher score reflects a better outcome.	Week -3, week 87
Change in IGFBP 3 SDS (Week 34)	Change in insulin like growth factor binding protein 3 (IGFBP 3) SDS was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in IGFBP 3 SDS (Week 87)	Change in IGFBP 3 SDS was measured from baseline (week -3) until the end of the extension treatment period (week 87).	Week -3, week 87
Change in TRIM-AGHD (Total and Domain Scores) (Week 34)	Change in treatment-related impact measure - adult growth hormone deficiency (TRIM-AGHD) scores (total and domain scores) was measured from baseline (week 0) until the end of the main treatment period (week 34). The TRIM-AGHD questionnaire measured the impact of GH treatment on the functioning and well-being of AGHD patients. The 4 concepts covered by the questionnaire were physical health, energy levels, cognitive ability and psychological health. TRIM-AGHD has 27 items and a total score as well as domain specific scores can be derived. The total score includes all answers that has been used to calculate each of the 4 subdomains. The score ranged from 0 to 100 for 'individual domains' and for the 'total', where a lower score reflected a better outcome.	Week 0, week 34
Change in TRIM-AGHD (Total and Domain Scores) (Week 87)	Change in TRIM-AGHD (total and domain scores) was measured from baseline (week 0) until the end of the extension treatment period (week 87). The TRIM-AGHD questionnaire measured the impact of GH treatment on the functioning and well-being of AGHD patients. The 4 concepts covered by the questionnaire were physical health, energy levels, cognitive ability and psychological health. TRIM-AGHD has 27 items and a total score as well as domain specific scores can be derived. The total score includes all answers that has been used to calculate each of the 4 subdomains. The score ranged from 0 to 100 for 'individual domains' and for the 'total', where a lower score reflected a better outcome.	week 0, week 87
Change in SF-36v2 (Summary and Domain Scores) (Week 34)	SF-36v2™ questionnaire measured health-related quality of life (HRQoL) on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (higher scores indicates better HRQoL) from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of the scores in the 2009 U.S. general population. Mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. Physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.	Week 0, week 34
Change in SF-36v2 (Summary and Domain Scores) (Week 87)	SF-36v2™ questionnaire measured health-related quality of life (HRQoL) on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (higher scores indicates better HRQoL) from SF-36 were converted to norm-based scores to enable a direct interpretation in relation to distribution of the scores in the 2009 U.S. general population. Mental component summary (MCS) measure is derived from domain scales of vitality, social functioning, role emotional and mental health. Physical component summary (PCS) measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicates an improvement since baseline.	week 0, week 87
TSQM-9 Scores (Domain Scores) (Week 34)	Scores from the TSQM-9 scale were calculated at the end of the main treatment period (week 34). The Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9) is a generic questionnaire that measures a patients' satisfaction with medication. Items are rated on a 5-point or 7-point scale according to patients' experience with the medication. The items covered are satisfaction with the effect of the medication, convenience and global treatment satisfaction. Each domain is based on 3 questions. The score is calculated in a range from 0 to 100, where a higher score reflects a better outcome. Scores have been summed and then scaled to 0-100.	Week 34
TSQM-9 Scores (Domain Scores) (Week 87)	Scores from the TSQM-9 scale were calculated at the end of the extension treatment period (week 87). The Treatment Satisfaction Questionnaire for Medication - 9 items (TSQM-9) is a generic questionnaire that measures a patients' satisfaction with medication. Items are rated on a 5-point or 7-point scale according to patients' experience with the medication. The items covered are satisfaction with the effect of the medication, convenience and global treatment satisfaction. Each domain is based on 3 questions. The score is calculated in a range from 0 to 100, where a higher score reflects a better outcome. Scores have been summed and then scaled to 0-100.	Week 87
Change in Total Cholesterol (Week 34)	Change in Total cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Total Cholesterol (Week 87)	Change in Total cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in HDL-cholesterol (Week 34)	Change in High-density lipoprotein (HDL) cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in HDL-cholesterol (Week 87)	Change in HDL-cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in LDL-cholesterol (Week 34)	Change in Low-density lipoprotein (LDL) cholesterol was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in LDL-cholesterol (Week 87)	Change in LDL-cholesterol was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Triglycerides (Week 34)	Change in Triglycerides was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Triglycerides (Week 87)	Change in Triglycerides was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Hs-CRP (Week 34)	Change in high-sensitivity C-reactive protein (hs-CRP) was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Hs-CRP (Week 87)	Change in hs-CRP was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in IL-6 (Week 34)	Change in Interleukin 6 (IL-6) was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in IL-6 (Week 87)	Change in IL-6 was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Body Weight (Week 34)	Change in body weight was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Body Weight (Week 87)	Change in body weight was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Waist Circumference (Week 34)	Change in waist circumference was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Waist Circumference (Week 87)	Change in waist circumference was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Number of Adverse Events (Weeks 0-35)	Number of adverse events from baseline (week 0) until the end of week 35 were reported. This endpoint shows number of treatment-emergent adverse events (TEAEs), including the injection site reactions.	Weeks 0-35
Number of Adverse Events (Weeks 0-88)	Number of adverse events from baseline (week 0) until the end of week 88 were reported. This endpoint shows the number of TEAEs along with the injection site reactions.	Weeks 0-88
Occurrence of Anti-NNC0195-0092 Antibodies (Weeks 0-35)	Number of participants with anti-NNC0195-0092 antibodies at week 35 was recorded. The numbers presented in this endpoint are the participants that were found to have positive antibodies.	Weeks 0 to 35
Occurrence of Anti-NNC0195-0092 Antibodies (Weeks 0-88)	Number of participants with anti-NNC0195-0092 antibodies at week 88 was recorded. The numbers presented in this endpoint are the participants that were found to have positive antibodies.	Weeks 0 to 88
Incidence of Technical Complaints During Exposure to Trial Product (Weeks 0-35)	Incidence of technical complaints were recorded from baseline (week 0) until week 35.	Weeks 0 to 35
Incidence of Technical Complaints During Exposure to Trial Product (Weeks 0-88)	Incidence of technical complaints were recorded from baseline (week 0) until week 88.	Weeks 0 to 88
Change in Physical Examination During Exposure to Trial Product (Week 35)	Change in physical examination from baseline (week 0) until the end of the main treatment period (week 35) was reported. Results are presented for the following examinations: 1) Head, neck, eyes and nose 2) Respiratory system (sys.) 3) Cardiovascular sys. 4) Gastrointestinal sys. 5) Musculoskeletal sys. 6) Central & Peripheral nervous sys. 7) Skin 8) Lymph node palpation	Week 0 and week 35
Change in Physical Examination During Exposure to Trial Product (Week 88)	Change in physical examination from baseline (week 0) until the end of the extension period (week 88) was reported. Results are presented for the following examinations: 1) Head, neck, eyes and nose 2) Respiratory system (sys.) 3) Cardiovascular sys. 4) Gastrointestinal sys. 5) Musculoskeletal sys. 6) Central & Peripheral nervous sys. 7) Skin 8) Lymph node palpation	Week 0 and week 88
Change in Electrocardiogram (ECG) Evaluation During Exposure to Trial Product (Week 35)	Change in Electrocardiogram (ECG) evaluation from baseline (week -3) until the end of the main treatment period (week 35) was reported.	Week -3 and week 35
Change in ECG Evaluation During Exposure to Trial Product (Week 88)	Change in ECG evaluation from baseline (week 0) until the end of the extension period (Week 88) was reported.	Week -3 and week 88
Change in Diastolic Blood Pressure (Week 35)	Change in diastolic blood pressure was measured from baseline (week -3) until the end of the main treatment period (week 35).	Week -3, week 35
Change in Diastolic Blood Pressure (Week 88)	Change in diastolic blood pressure was measured from baseline (week -3) until the end of the extension treatment period week 88.	Week -3, week 88
Change in Systolic Blood Pressure (Week 35)	Change in systolic blood pressure was measured from baseline (week -3) until the end of the main treatment period (week 35).	Week -3, week 35
Change in Systolic Blood Pressure (Week 88)	Change in systolic blood pressure was measured from baseline (week -3) until the end of the extension treatment period (week 88).	Week -3, week 88
Change in Pulse (Week 35)	Change in pulse was measured from baseline (week -3) until the end of the main treatment period (week 35).	Week -3, week 35
Change in Pulse (Week 88)	Change in pulse was measured from baseline (week -3) until the end of the extension treatment period (week 88).	Week -3, week 88
Change in Haemoglobin (Week 34)	Change in Haemoglobin was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Haemoglobin (Week 87)	Change in Haemoglobin was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Haematocrit (Week 34)	Change in Haematocrit was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Haematocrit (Week 87)	Change in Haematocrit was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Erythrocytes (Week 34)	Change in Erythrocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Erythrocytes (Week 87)	Change in Erythrocytes was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Mean Corpuscular Volume (MCV) (Week 34)	Change in Mean corpuscular volume (MCV) was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Mean Corpuscular Volume (MCV) (Week 87)	Change in Mean corpuscular volume (MCV) was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Mean Corpuscular Haemoglobin Concentration (MCHC) (Week 34)	Change in Mean corpuscular haemoglobin concentration (MCHC) was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Mean Corpuscular Haemoglobin Concentration (MCHC) (Week 87)	Change in Mean corpuscular haemoglobin concentration (MCHC) was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Thrombocytes (Week 34)	Change in Thrombocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Thrombocytes (Week 87)	Change in Thrombocytes was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Leucocytes (Week 34)	Change in Leucocytes was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Leucocytes (Week 87)	Change in Leucocytes was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Alanine Aminotransferase (ALT) (Week 34)	Change in ALT was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Alanine Aminotransferase (ALT) (Week 87)	Change in ALT was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Albumin (Week 34)	Change in Albumin was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Albumin (Week 87)	Change in Albumin was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Alkaline Phosphatase (ALP) (Week 34)	Change in Alkaline phosphatase (ALP) was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Alkaline Phosphatase (AP) (Week 87)	Change in Alkaline phosphatase (AP) was measured from baseline (week -3) until the end of the week 87.	Week -3, week 87
Change in Aspartate Aminotransferase (AST) (Week 34)	Change in AST was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Aspartate Aminotransferase (AST) (Week 87)	Change in AST was measured from baseline (week -3) until the end of the extension treatment period (week 87).	Week -3, week 87
Change in Bilirubin (Week 34)	Change in Bilirubin was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Bilirubin (Week 87)	Change in Bilirubin was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Calcium (Week 34)	Change in Calcium was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Calcium (Week 87)	Change in Calcium was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Chloride (Week 34)	Change in Chloride was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Chloride (Week 87)	Change in Chloride was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Creatinine (Week 34)	Change in Creatinine was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Creatinine (Week 87)	Change in Creatinine was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Creatine Kinase (Week 34)	Change in Creatine kinase was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Creatine Kinase (Week 87)	Change in Creatine kinase was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Gamma-glutamyl Transferase (GGT) (Week 34)	Change in GGT was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Gamma-glutamyl Transferase (GGT) (Week 87)	Change in GGT was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Phosphate (Inorganic) (Week 34)	Change in Phosphate (inorganic) was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Phosphate (Inorganic)(Week 87)	Change in Phosphate (inorganic) was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Potassium (Week 34)	Change in Potassium was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Potassium (Week 87)	Change in Potassium was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Sodium (Week 34)	Change in Sodium was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Sodium (Week 87)	Change in Sodium was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Total Protein (Week 34)	Change in total protein was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Total Protein (Week 87)	Change in total protein was measured from baseline (week -3) until the end of extension treatment period (week 87).	week -3, week 87
Change in Urea (Week 34)	Change in Urea was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Urea (Week 87)	Change in Urea was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Uric Acid (Week 34)	Change in Uric acid was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Uric Acid (Week 87)	Change in Uric acid was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Estimated Glomerular Filtration Rate (GFR) Creatinine (CKD-EPI) (Week 34)	Change in Estimated GFR creatinine (CKD-EPI) was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Estimated GFR Creatinine (CKD-EPI) (Week 87)	Change in estimated GFR creatinine (CKD-EPI) was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Fasting Plasma Glucose (Week 34)	Change in Fasting plasma glucosewas measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Fasting Plasma Glucose (Week 87)	Change in Fasting plasma glucose was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Fasting Insulin (Week 34)	Change in Fasting insulin was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Fasting Insulin (Week 87)	Change in Fasting insulin was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Steady State Beta Cell Function (%B) (Week 34)	Change in steady state beta cell function (%B) was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Steady State Beta Cell Function (%B) (Week 87)	Change in steady state beta cell function (%B) was measured from baseline (week -3) until the end of the week 87.	week -3, week 87
Change in Insulin Resistance (IR %) (Week 34)	Change in Insulin resistance (IR %) was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Insulin Resistance (IR %) (Week 87)	Change in Insulin resistance (IR %) was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87
Change in Glycated Haemoglobin (HbA1c) (%) (Week 34)	Change in Glycated haemoglobin (HbA1c) (%) was measured from baseline (week -3) until the end of the main treatment period (week 34).	Week -3, week 34
Change in Glycated Haemoglobin (HbA1c) (%) (Week 87)	Change in Glycated haemoglobin (HbA1c) was measured from baseline (week -3) until the end of the extension treatment period (week 87).	week -3, week 87

Collaborators and Investigators

• Sponsor: Novo Nordisk A/S
• Investigators: Study Director: Clinical Reporting Anchor and Disclosure' (1452), Novo Nordisk A/S

Publications and helpful links

General Publications

• Takahashi Y, Biller BMK, Fukuoka H, Ho KKY, Rasmussen MH, Nedjatian N, Svaerke C, Yuen KCJ, Johannsson G. Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency. Pituitary. 2022 Nov 15. doi: 10.1007/s11102-022-01283-3. Online ahead of print.
• Johannsson G, Gordon MB, Hojby Rasmussen M, Hakonsson IH, Karges W, Svaerke C, Tahara S, Takano K, Biller BMK. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial. J Clin Endocrinol Metab. 2020 Apr 1;105(4):e1358-76. doi: 10.1210/clinem/dgaa049.

Helpful Links

• Clinical Trials at Novo Nordisk

Study record dates

Study Major Dates

• Study Start (Actual): October 31, 2014
• Primary Completion (Actual): April 21, 2017
• Study Completion (Actual): May 7, 2018

Study Registration Dates

• First Submitted: August 26, 2014
• First Submitted That Met QC Criteria: September 2, 2014
• First Posted (Estimate): September 3, 2014

Study Record Updates

• Last Update Posted (Actual): November 23, 2020
• Last Update Submitted That Met QC Criteria: November 3, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Musculoskeletal Diseases; Hypothalamic Diseases; Bone Diseases; Bone Diseases, Endocrine; Pituitary Diseases; Dwarfism; Bone Diseases, Developmental; Hypopituitarism; Dwarfism, Pituitary; Endocrine System Diseases
• Other Study ID Numbers: NN8640-4054; 2013-002892-16 (Registry Identifier: European Medicines Agency); U1111-1145-0211 (Other Identifier: World Health Organization (WHO)); JapicCTI-152767 (Registry Identifier: JAPIC)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No